|
BSX Meets With Much Approval, Biogen and Icahn Set the (Showdown) Date, Fate’s Fate Revealed, Win Free Stuff, & More Life Sciences News
|
Rebecca Zacks |
05/14/08 |
|
No Comments
|
|
Biogen Idec Sets Date for Showdown With Icahn, Proxy Battle Begins
|
Robert Buderi |
05/09/08 |
|
No Comments
|
|
Three Luminaries, Two Third Revolutions, and One Nice Suit: An Xconomy Forum on the Future of Life Sciences in New England
|
Rebecca Zacks |
05/02/08 |
|
No Comments
|
|
Take Two Blueberry Jelly Beans and Call Me in the Morning: Cambridge Biotech’s Best and Brightest on Show (or Not)
|
Erik Mellgren |
05/02/08 |
|
1 Comment
|
|
ZS Genetics Enters the X Prize Fray, Biogen Falls on Rituxan News, Acusphere Takes a Step Toward Clinical Finish Line, & More Life Sciences News
|
Rebecca Zacks |
04/30/08 |
|
No Comments
|
|
GSK Takes Sirtris and Taps Alnylam Venture, FDA Deals Genzyme Drug a Blow, Resolvyx Finances Fish-Oil Drugs, & More Life Sciences News
|
Rebecca Zacks |
04/23/08 |
|
No Comments
|
|
Resolvyx gets $25 Million in Financing to Turn Fish-Oil Science into New Drugs
|
Erik Mellgren |
04/22/08 |
|
No Comments
|
|
With a $25 Million Bankroll and Technology “Fully Baked” by Biogen Idec, Stromedix is Heading into the Uncharted Territory of Fibrosis
|
Rebecca Zacks |
04/21/08 |
|
No Comments
|
|
Biogen Idec Announces Its Own Director Slate—Digs in Against Icahn
|
Robert Buderi |
04/17/08 |
|
No Comments
|
|
A Lawsuit for Biogen, A Suitor for Millennium, The Suits Who Made Their Own Fate, & More Life Sciences News
|
Rebecca Zacks |
04/16/08 |
|
No Comments
|
|
Icahn Turns Up Heat, Files Suit to Force Biogen Idec to Turn Over Records of Failed Sale
|
Robert Buderi |
04/09/08 |
|
No Comments
|
|
In Latest Local Venture Philanthropy Deal, Cystic Fibrosis Foundation Pledges up to $37.7 More to Epix
|
Rebecca Zacks |
04/07/08 |
|
No Comments
|
|
Biogen’s Busy Week, Alnylam’s Big Announcement, Targanta’s and Momenta’s Growing Executive Ranks, & More Life Sciences News
|
Rebecca Zacks |
03/05/08 |
|
No Comments
|
|
Novell Gets Into Virtualization, 38 Studios Gets Into Virtual Worlds, Mascoma Raises Some Real Money, & More
|
Rebecca Zacks |
03/03/08 |
|
No Comments
|
|
Biogen Idec Sells $1B in Notes, Converting Bridge Loan to Permanent Debt
|
Robert Buderi |
02/28/08 |
|
No Comments
|
|
Biogen Bouncing Back From Tysabri Warning News
|
Rebecca Zacks |
02/28/08 |
|
1 Comment
|
|
Fearing Icahn’s Impact on Morale, Biogen Idec Launches Key Employee Retention Plan
|
Robert Buderi |
02/15/08 |
|
No Comments
|
|
Icahn Dumps Genzyme Position
|
Robert Buderi |
02/14/08 |
|
1 Comment
|
|
With a Whole Lot of Spending to Do, Vertex Seeks Some $400 Million in Stock and Note Offerings
|
Rebecca Zacks |
02/13/08 |
|
No Comments
|
|
Biogen Idec: Earnings Up, Gauntlet Down, Headhunters All Around?
|
Rebecca Zacks |
02/07/08 |
|
No Comments
|
|
Barbs of Wisdom: Carl Icahn to Start Blogging
|
Robert Buderi |
02/06/08 |
|
No Comments
|
|
ImmunoGen Scores $1.5M From Biogen Idec
|
Rebecca Zacks |
02/04/08 |
|
No Comments
|
|
An Analysis of Icahn’s Biogen Idec Strategy: Why Three Board Seats When Four Will Be Open?
|
Robert Buderi |
01/31/08 |
|
No Comments
|
|
Icahn to Nominate Three, Including Two Harvard Bigwigs, to Biogen Idec Board
|
Rebecca Zacks |
01/28/08 |
|
No Comments
|
|
MIT Teams With Italian Energy Giant, Elixir Postpones Its IPO, Biogen Idec Will Buy or Be Bought, & More
|
Rebecca Zacks |
01/23/08 |
|
No Comments
|
|
Icahn: Biogen Idec Will Be Bought
|
Robert Buderi |
01/16/08 |
|
No Comments
|
|
Biogen Idec’s Tysabri Approved for Crohn’s
|
Rebecca Zacks |
01/14/08 |
|
No Comments
|
|
Perceived Risk, Culture Clash Did in Biogen Idec Sale, CEO Asserts
|
Henry Johnson |
01/11/08 |
|
2 Comments
|
|
Tempo Steps Up The Funding Pace
|
Robert Buderi |
01/03/08 |
|
No Comments
|
|
The Xconomy Half-Dozen-Stories-of-the-Half-Year Awards
|
Rebecca Zacks |
12/27/07 |
|
1 Comment
|
